“Top 25 Vaccines market set to grow to $41bn by 2024” says new Visiongain report

27 February 2020
Pharma

Visiongain has launched a new pharma report Top 25 Vaccines Market Forecast to 2029: Prevnar/Prevnar 13; Gardasil/Gardasil 9; Fluzone/Vaxigrip; Pentacel; Infanrix, Pediarix; GSK Hepatitis Vaccine; Pneumovax 23; Varivax; Bexsero; Boostrix; Menactra; RotaTeq; Rotarix; Zostavax; Synflorix; FluLaval/Fluarix; ProQuad; M-M-R II; Adacel; Menveo; Repevax; Cervarix; FSME/IMMUN-TicoVac; Ixiaro; FluMist/Fluenz.

Visiongain predicts that the overall global market, submarket and product revenues will continue to grow, with human vaccines driving the sales of pharmaceutical companies. The industry will see entry of new key players and advancements in technology, overall resulting in an increase in market size of the world human vaccines market.

The lead analyst of the report commented "There is an increasing focus to identify diseases that currently do not have a vaccine. This breeds a strong platform for both start-ups and larger pharmaceutical companies to create new vaccines that are not already on the market. This prevents stagnation within the market and will help drive the growth of the human vaccines market.

The media is playing an increasingly important role in spreading awareness about the complications of various infectious diseases if the public is not immunized. The increasing levels of awareness has promoted the benefits of vaccines as the most effective form of immunization against infection, consequently leading to increased demand for the vaccines."

Leading companies featured in the report include AstraZeneca, Eli Lilly, Emergent BioSolutions Inc., GlaxoSmithKline, Johnson & Johnson, Merck & Co., Pfizer, Sanofi, Serum Institute of India Private Limited, Takeda and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Generic Drugs Market Report 2020-2030

The 431-page report provides clear detailed insight into the generic drugs market. Discover the key drivers and challenges affecting the market.

03 July 2020

Read

Visiongain publishes Clinical Workflow Solutions Market Report 2020-2030

Where is the Clinical Workflow Solutions market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.

03 July 2020

Read

Visiongain Publishes Clinical Trials Market Report 2020-2030

With the growing burden of rare diseases around the world, there has been a rise and advancement in the therapy development of these types of diseases. While the fact remains that over 90% of these diseases lack approval for treatment and the total number of terminal rare diseases to receive the first treatment every year remains low.

01 July 2020

Read

Visiongain Publishes Clinical Risk Grouping Solutions Market Report 2020-2030

The market growth is attributed to the growing adoption of big data and AI in data management and monitoring of clinical information in health care.

01 July 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever